"Antibodies, Neutralizing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies that reduce or abolish some biological activity of a soluble antigen or infectious agent, usually a virus.
| Descriptor ID |
D057134
|
| MeSH Number(s) |
D12.776.124.486.485.114.244 D12.776.124.790.651.114.244 D12.776.377.715.548.114.244
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neutralizing".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neutralizing".
This graph shows the total number of publications written about "Antibodies, Neutralizing" by people in this website by year, and whether "Antibodies, Neutralizing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 2 | 0 | 2 |
| 2011 | 5 | 2 | 7 |
| 2012 | 7 | 1 | 8 |
| 2013 | 4 | 0 | 4 |
| 2014 | 5 | 1 | 6 |
| 2015 | 10 | 2 | 12 |
| 2016 | 8 | 7 | 15 |
| 2017 | 10 | 1 | 11 |
| 2018 | 10 | 3 | 13 |
| 2019 | 6 | 4 | 10 |
| 2020 | 6 | 8 | 14 |
| 2021 | 8 | 9 | 17 |
| 2022 | 1 | 14 | 15 |
| 2023 | 1 | 12 | 13 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
SARS-CoV-2 BA.4/5 infection triggers more cross-reactive Fc?RIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. J Virol. 2024 Jul 23; 98(7):e0067824.
-
Evaluating the antibody response elicited by diverse HIV envelope immunogens in the African green monkey (Vervet) model. Sci Rep. 2024 06 10; 14(1):13311.
-
Comparable safety and non-inferior immunogenicity of the SARS-CoV-2 mRNA vaccine candidate PTX-COVID19-B and BNT162b2 in a phase 2 randomized, observer-blinded study. Sci Rep. 2024 03 04; 14(1):5365.
-
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features. Proc Natl Acad Sci U S A. 2024 Jan 23; 121(4):e2308942121.
-
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials. Nat Commun. 2023 Dec 14; 14(1):8299.
-
Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines. J Virol. 2024 Jan 23; 98(1):e0147823.
-
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection. PLoS Pathog. 2023 Nov; 19(11):e1011772.
-
Evaluation of a human mucosal tissue explant model for SARS-CoV-2 replication. PLoS One. 2023; 18(9):e0291146.
-
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial. J Infect Dis. 2023 08 11; 228(3):299-310.
-
Despite delayed kinetics, people living with HIV achieve equivalent antibody function after SARS-CoV-2 infection or vaccination. Front Immunol. 2023; 14:1231276.